Ferric sulfate
Identification
- Summary
Ferric sulfate is a medication used as a coagulant and hemostatic agent.
- Generic Name
- Ferric sulfate
- DrugBank Accession Number
- DB11171
- Background
Ferric sulfate has the molecular formula of Fe2SO4, and it is a dark brown or yellow chemical agent with acidic properties. It is produced by the reaction of sulfuric acid and an oxidizing agent. It is used in different fields such as dermatology, dentistry and it is thought to present hemostatic properties by interacting chemically with blood proteins.1,2 By the FDA, ferric sulfate is a direct food substance affirmed in the GRAS category (Generally Recognized As Safe).6
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 489.93
Monoisotopic: 489.777884 - Chemical Formula
- Fe2H10O17S3
- Synonyms
- Ferric sulfate
Pharmacology
- Indication
Ferric sulfate was first used in dermatology as part of the Monsel's solution. This solution is an antihemorrhagic agent used in skin and mucosal biopsies. The use of ferric sulfate in dermatology is under review as ferric sulfate is corrosive and injurious and it can cause degenerative changes that are not observed with other alternatives like collagen.3
Ferric sulfate is also used as a coagulative and hemostatic agent. It is a mechanic hemostatic agent used directly on the damaged tissue.1
In dentistry, ferric sulfate is used as a pulpotomy medicament to control pulpal bleeding, as an antibacterial agent and as a hemostatic reagent for restorative dentistry, for postextraction hemorrhage and for periradicular and endodontic surgery.2
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
The administration of ferric sulfate as a dermatologic agent has showed delayed reepithelialization and dyspigmentation. Some studies have reported the generation of inflammation in the sites of administration of ferric sulfate.2
- Mechanism of action
The main function of ferric sulfate is as a hemostatic agent in different medical practices. This hemostatic function is achieved when ferric sulfate is applied directly in the damaged tissue. Once applied, ferric sulfate forms ferric ion-protein complex which helps the sealing of the damaged vessels mechanically. The formation of agglutinated protein complexes produces the generation of occlusion in the capillary orifices.4 The formation of the ferric protein complex is thought to be due to a chemical reaction between the acidic form of ferric sulfate and the blood proteins.5
- Absorption
Pharmacokinetic studies related to the absorption of ferric sulfate have not been performed.
- Volume of distribution
Pharmacokinetic studies related to the volume of distribution of ferric sulfate have not been performed.
- Protein binding
Ferric sulfate presents very high protein binding properties, this property is thought to be due to its acidic profile.5
- Metabolism
Pharmacokinetic studies related to the metabolism of ferric sulfate have not been performed.
- Route of elimination
Pharmacokinetic studies related to the elimination of ferric sulfate have not been performed.
- Half-life
Pharmacokinetic studies related to the half-life of ferric sulfate have not been performed.
- Clearance
Pharmacokinetic studies related to the clearance of ferric sulfate have not been performed.
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Ferric sulfate has been proven to be an irritating substance into the eye, throat, gastrointestinal and respiratory tract.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid Ferric sulfate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Almasilate Almasilate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. Asenapine Asenapine can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Active Moieties
Name Kind UNII CAS InChI Key Ferric cation ionic 91O4LML611 20074-52-6 VTLYFUHAOXGGBS-UHFFFAOYSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image FasTRACT Topical Hemostat Gel 142 mg/1 Intragingival Cao Group, Inc. 2016-02-08 2018-10-09 US FastStat Topical Hemostat Gel 142 mg/1g Intragingival Cao Group, Inc. 2010-09-01 2018-10-11 US Statis Hemostyptic Soln 210mg/ml Liquid 210 mg / mL Dental Gingi Pak Labs, Division Of Belport Co., Inc. 1986-12-31 2004-08-16 Canada - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ferrostat Liq 21% Liquid 21 % Dental Hoechst Roussel Canada Inc. 1995-12-31 1997-11-19 Canada Hemodent FS Liquid 15.5 % Topical Premier Dental Products Company 1997-12-10 1998-07-02 Canada Stasis Solution 3150 mg/15mL Dental; Oral; Periodontal Gingi-Pak a Division of the Belport 1987-06-26 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image FasTRACT Topical Hemostat Ferric sulfate (142 mg/1) Gel Intragingival Cao Group, Inc. 2016-02-08 2018-10-09 US FastStat Topical Hemostat Ferric sulfate (142 mg/1g) Gel Intragingival Cao Group, Inc. 2010-09-01 2018-10-11 US Stasis Ferric sulfate (3150 mg/15mL) Solution Dental; Oral; Periodontal Gingi-Pak a Division of the Belport 1987-06-26 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as transition metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is a transition metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Transition metal oxoanionic compounds
- Sub Class
- Transition metal sulfates
- Direct Parent
- Transition metal sulfates
- Alternative Parents
- Inorganic salts / Inorganic oxides
- Substituents
- Inorganic oxide / Inorganic salt / Transition metal sulfate
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 3HWS7HF5XD
- CAS number
- 10028-22-5
- InChI Key
- YHGPYBQVSJBGHH-UHFFFAOYSA-H
- InChI
- InChI=1S/2Fe.3H2O4S.5H2O/c;;3*1-5(2,3)4;;;;;/h;;3*(H2,1,2,3,4);5*1H2/q2*+3;;;;;;;;/p-6
- IUPAC Name
- diiron(3+) ion pentahydrate trisulfate
- SMILES
- O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
References
- General References
- Nouri S, Sharif MR: Use of ferric sulfate to control hepatic bleeding. Trauma Mon. 2015 Feb;20(1):e25257. doi: 10.5812/traumamon.25257. Epub 2015 Jan 1. [Article]
- Bandi M, Mallineni SK, Nuvvula S: Clinical applications of ferric sulfate in dentistry: A narrative review. J Conserv Dent. 2017 Jul-Aug;20(4):278-281. doi: 10.4103/JCD.JCD_259_16. [Article]
- Olmstead PM, Lund HZ, Leonard DD: Monsel's solution: a histologic nuisance. J Am Acad Dermatol. 1980 Nov;3(5):492-8. [Article]
- EPSTEIN E, MAIBACH HI: MONSEL'S SOLUTION; HISTORY, CHEMISTRY, AND EFFICACY. Arch Dermatol. 1964 Aug;90:226-8. [Article]
- Smith NL, Seale NS, Nunn ME: Ferric sulfate pulpotomy in primary molars: a retrospective study. Pediatr Dent. 2000 May-Jun;22(3):192-9. [Article]
- FDA Code of Federal Regulations [Link]
- External Links
- PubChem Compound
- 23443659
- PubChem Substance
- 347827931
- ChemSpider
- 11640309
- 24913
- Wikipedia
- Iron(III)_sulfate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Anemia of Pregnancy / Iron Deficiency Anemia (IDA) / Low Birth Weight Infants 1 3 Completed Treatment Extensive Decay in Primary Molars 1 0 Recruiting Treatment Pulpitis dental 1 Not Available Active Not Recruiting Not Available Autism Disorder / Iron Deficiency Anemia (IDA) / Neurodevelopmental Abnormality 1 Not Available Active Not Recruiting Not Available Development, Child / Fetal Neurodevelopmental Disorder / Iron Deficiency Anemia (IDA) / Iron Deficiency Anemia of Pregnancy / Iron Deficiency Anemia Treatment / Neurodevelopmental Disorder of Foetus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Gel Intragingival 142 mg/1 Gel Intragingival 142 mg/1g Liquid Dental 21 % Liquid Topical 15.5 % Solution Dental; Oral; Periodontal 3150 mg/15mL Liquid Dental 210 mg / mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) The Anhydrous form decomposes (480ºC) 'MSDS' boiling point (°C) The Anhydrous form decomposes (480ºC) 'MSDS' water solubility Soluble at room temperature Bandi, et al. J Conserv Dent. (2017) - Predicted Properties
Property Value Source logP -0.84 Chemaxon pKa (Strongest Acidic) -3 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 80.26 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 11.53 m3·mol-1 Chemaxon Polarizability 5.81 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 03, 2015 16:51 / Updated at February 21, 2021 18:52